Klotho Conference 2025 Advances Research on Protein's Role in Healthspan Extension

The inaugural Klotho Conference & Scientific Seminar, held September 15–16 at the UCI Beall Applied Innovation Center, brought together leading researchers, clinicians, and innovators to discuss recent Klotho biology research, its therapeutic potential, and diagnostic advances. This landmark event marked a significant step forward in translating decades of Klotho research into actionable strategies for healthspan extension. Conference presentations are available in a playlist of all Klotho Conference presentations.

The conference opened with a "State of the Industry" address by Menachem Abraham, followed by a keynote from Dr. Makoto Kuroo, who discovered the Klotho gene. Their talks framed the current landscape of Klotho research, from molecular pathways to clinical translation. Carmela Abraham presented results of a Klotho-mRNA-LNP approach to increasing Klotho levels, while Petr Sramek presented compelling human case studies exploring Klotho-based therapies, shedding light on the translational journey from preclinical models to patient outcomes.

A dedicated panel, led by Dr. Dena Dubal and Dr. Miguel Chillon, examined emerging evidence for Klotho's neuroprotective role including its impact on neurodegenerative disease models and its potential for gene therapy applications. Dr. Ido Wolf and Dr. Tamar Rubinek summarized their research on the potential of Klotho in malignant tumors suppression. Dr. Assumpció Bosch delivered a presentation on Klotho gene therapy for ALS, outlining preclinical progress and the roadmap for future clinical trials.

Inflammation-focused research was a major topic: Dr. Iliya Lefterov and Dr. Radosveta Koldamova discussed how Klotho signaling intersects with inflammatory pathways and its implications for chronic disease and aging. A panel including Dr. Mona EzzatVilinov and celebrity fitness expert Ramona Braganza explored Klotho's role in muscle regeneration, functional mobility, and exercise-driven healthspan. Dr. Gail Humble discussed cutting-edge research into Klotho's use in medical aesthetics — covering skin, hair, and tissue regeneration.

Dr. Doris Taylor closed out major talks with her visionary presentation on Klotho's regenerative applications for organs and cardiovascular tissue. Dr. Ian White delivered a keynote outlining the translational path for Klotho therapies, including how naturally derived human Klotho sources can move into clinical trial phases. Dr. Joseph Cleaver gave a luncheon keynote on lifestyle, aging, and Klotho — synthesizing scientific insight with practical takehome messages for wellness practitioners.

Research indicates that low circulating Klotho levels are associated with accelerated aging and increased risks for numerous health conditions. Studies have linked low Klotho to higher cancer risk, earlier cognitive decline, increased likelihood of brain disorders, higher risk of heart and kidney failure, elevated calcification and inflammation, muscle atrophy, sarcopenia, and various age-related conditions affecting vision, hearing, bone strength, and skin health. Low Klotho also leads to higher oxidative stress, mitochondrial dysfunction, increased susceptibility to infections, slower wound healing, accelerated telomere shortening, epigenetic age acceleration, and reduced healthspan and longevity. Studies are underway to determine if higher Klotho levels can reverse these effects.

Attendees engaged in interactive Q&A sessions and roundtables to build collaborative pathways for Klotho research and commercialization. Several research groups indicated plans to accelerate clinical development of Klotho-based gene therapies. The conference catalyzed new partnerships, including academic institutions, biotech companies, and longevity-focused investor networks. It reinforced the unified mission: raising Klotho biology into mainstream medical and therapeutic strategy to promote healthy aging. The success of this first Klotho Conference sets the stage for annual gatherings to follow. Organizers announced that future conferences will expand to include translational clinical trials, diagnostics development, and policy frameworks to bring Klotho therapies to patients responsibly and equitably.